vs
科睿唯安（CLVT）与SiriusPoint Ltd（SPNT）财务数据对比。点击上方公司名可切换其他公司
SiriusPoint Ltd的季度营收约是科睿唯安的1.6倍（$973.7M vs $617.0M），SiriusPoint Ltd净利率更高（25.1% vs 0.5%，领先24.6%），SiriusPoint Ltd同比增速更快（58.9% vs -6.9%），过去两年SiriusPoint Ltd的营收复合增速更高（19.2% vs -0.3%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
SiriusPoint Ltd是一家总部位于百慕大彭布罗克的全球特种保险及再保险服务商，提供财产险、意外险、特种险种保障及另类资本解决方案，服务覆盖北美、欧洲、亚太等市场的商业客户与风险承担方，注重严谨核保与稳定的风险调整收益。
CLVT vs SPNT — 直观对比
营收规模更大
SPNT
是对方的1.6倍
$617.0M
营收增速更快
SPNT
高出65.8%
-6.9%
净利率更高
SPNT
高出24.6%
0.5%
两年增速更快
SPNT
近两年复合增速
-0.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $617.0M | $973.7M |
| 净利润 | $3.1M | $244.1M |
| 毛利率 | 66.8% | — |
| 营业利润率 | 6.7% | 28.8% |
| 净利率 | 0.5% | 25.1% |
| 营收同比 | -6.9% | 58.9% |
| 净利润同比 | 101.6% | 1535.9% |
| 每股收益（稀释后） | $0.00 | $1.92 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTSPNT
| Q4 25 | $617.0M | $973.7M | ||
| Q3 25 | $623.1M | $755.9M | ||
| Q2 25 | $621.4M | $748.2M | ||
| Q1 25 | $593.7M | $727.3M | ||
| Q4 24 | $663.0M | $612.8M | ||
| Q3 24 | $622.2M | $562.2M | ||
| Q2 24 | $650.3M | $743.3M | ||
| Q1 24 | $621.2M | $685.5M |
净利润CLVTSPNT
| Q4 25 | $3.1M | $244.1M | ||
| Q3 25 | $-28.3M | $90.8M | ||
| Q2 25 | $-72.0M | $63.2M | ||
| Q1 25 | $-103.9M | $61.6M | ||
| Q4 24 | $-191.8M | $-17.0M | ||
| Q3 24 | $-65.6M | $8.5M | ||
| Q2 24 | $-304.3M | $113.9M | ||
| Q1 24 | $-75.0M | $94.8M |
毛利率CLVTSPNT
| Q4 25 | 66.8% | — | ||
| Q3 25 | 65.0% | — | ||
| Q2 25 | 67.2% | — | ||
| Q1 25 | 65.1% | — | ||
| Q4 24 | 65.7% | — | ||
| Q3 24 | 66.2% | — | ||
| Q2 24 | 67.2% | — | ||
| Q1 24 | 64.9% | — |
营业利润率CLVTSPNT
| Q4 25 | 6.7% | 28.8% | ||
| Q3 25 | 7.1% | 14.7% | ||
| Q2 25 | 1.1% | 10.0% | ||
| Q1 25 | -3.5% | 10.4% | ||
| Q4 24 | -9.4% | -2.1% | ||
| Q3 24 | 3.5% | 2.0% | ||
| Q2 24 | -36.9% | 17.4% | ||
| Q1 24 | 0.8% | 15.4% |
净利率CLVTSPNT
| Q4 25 | 0.5% | 25.1% | ||
| Q3 25 | -4.5% | 12.0% | ||
| Q2 25 | -11.6% | 8.4% | ||
| Q1 25 | -17.5% | 8.5% | ||
| Q4 24 | -28.9% | -2.8% | ||
| Q3 24 | -10.5% | 1.5% | ||
| Q2 24 | -46.8% | 15.3% | ||
| Q1 24 | -12.1% | 13.8% |
每股收益（稀释后）CLVTSPNT
| Q4 25 | $0.00 | $1.92 | ||
| Q3 25 | $-0.04 | $0.73 | ||
| Q2 25 | $-0.11 | $0.50 | ||
| Q1 25 | $-0.15 | $0.49 | ||
| Q4 24 | $-0.27 | $-0.05 | ||
| Q3 24 | $-0.09 | $0.03 | ||
| Q2 24 | $-0.46 | $0.57 | ||
| Q1 24 | $-0.14 | $0.49 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $329.2M | $731.2M |
| 总债务越低越好 | $4.3B | $688.6M |
| 股东权益账面价值 | $4.8B | $2.5B |
| 总资产 | $11.1B | $12.6B |
| 负债/权益比越低杠杆越低 | 0.89× | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资CLVTSPNT
| Q4 25 | $329.2M | $731.2M | ||
| Q3 25 | $318.7M | $582.4M | ||
| Q2 25 | $362.6M | $732.4M | ||
| Q1 25 | $354.0M | $740.3M | ||
| Q4 24 | $295.2M | $682.0M | ||
| Q3 24 | $388.5M | $640.7M | ||
| Q2 24 | $376.4M | $598.1M | ||
| Q1 24 | $361.8M | $867.5M |
总债务CLVTSPNT
| Q4 25 | $4.3B | $688.6M | ||
| Q3 25 | $4.4B | $682.5M | ||
| Q2 25 | $4.5B | $678.4M | ||
| Q1 25 | $4.5B | $663.5M | ||
| Q4 24 | $4.5B | $639.1M | ||
| Q3 24 | $4.6B | $660.5M | ||
| Q2 24 | $4.6B | $648.6M | ||
| Q1 24 | $4.6B | $770.6M |
股东权益CLVTSPNT
| Q4 25 | $4.8B | $2.5B | ||
| Q3 25 | $4.9B | $2.2B | ||
| Q2 25 | $5.0B | $2.1B | ||
| Q1 25 | $5.0B | $2.0B | ||
| Q4 24 | $5.1B | $1.9B | ||
| Q3 24 | $5.5B | $2.7B | ||
| Q2 24 | $5.6B | $2.7B | ||
| Q1 24 | $5.9B | $2.6B |
总资产CLVTSPNT
| Q4 25 | $11.1B | $12.6B | ||
| Q3 25 | $11.2B | $12.5B | ||
| Q2 25 | $11.4B | $12.4B | ||
| Q1 25 | $11.5B | $12.3B | ||
| Q4 24 | $11.5B | $12.5B | ||
| Q3 24 | $12.0B | $12.7B | ||
| Q2 24 | $12.1B | $12.8B | ||
| Q1 24 | $12.5B | $13.1B |
负债/权益比CLVTSPNT
| Q4 25 | 0.89× | 0.28× | ||
| Q3 25 | 0.90× | 0.31× | ||
| Q2 25 | 0.90× | 0.32× | ||
| Q1 25 | 0.90× | 0.33× | ||
| Q4 24 | 0.88× | 0.33× | ||
| Q3 24 | 0.84× | 0.25× | ||
| Q2 24 | 0.83× | 0.24× | ||
| Q1 24 | 0.79× | 0.30× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.9M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $89.2M | — |
| 自由现金流率自由现金流/营收 | 14.5% | — |
| 资本支出强度资本支出/营收 | 11.5% | — |
| 现金转化率经营现金流/净利润 | 51.58× | -0.11× |
| 过去12个月自由现金流最近4个季度 | $365.3M | — |
8季度趋势，按日历期对齐
经营现金流CLVTSPNT
| Q4 25 | $159.9M | $-26.4M | ||
| Q3 25 | $181.1M | $155.6M | ||
| Q2 25 | $116.3M | $62.1M | ||
| Q1 25 | $171.2M | $-88.9M | ||
| Q4 24 | $141.3M | $107.7M | ||
| Q3 24 | $202.9M | $58.1M | ||
| Q2 24 | $126.2M | $-149.9M | ||
| Q1 24 | $176.2M | $58.8M |
自由现金流CLVTSPNT
| Q4 25 | $89.2M | — | ||
| Q3 25 | $115.5M | — | ||
| Q2 25 | $50.3M | — | ||
| Q1 25 | $110.3M | — | ||
| Q4 24 | $59.1M | — | ||
| Q3 24 | $126.3M | — | ||
| Q2 24 | $60.3M | — | ||
| Q1 24 | $111.8M | — |
自由现金流率CLVTSPNT
| Q4 25 | 14.5% | — | ||
| Q3 25 | 18.5% | — | ||
| Q2 25 | 8.1% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 20.3% | — | ||
| Q2 24 | 9.3% | — | ||
| Q1 24 | 18.0% | — |
资本支出强度CLVTSPNT
| Q4 25 | 11.5% | — | ||
| Q3 25 | 10.5% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 10.3% | — | ||
| Q4 24 | 12.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | 10.1% | — | ||
| Q1 24 | 10.4% | — |
现金转化率CLVTSPNT
| Q4 25 | 51.58× | -0.11× | ||
| Q3 25 | — | 1.71× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | -1.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.84× | ||
| Q2 24 | — | -1.32× | ||
| Q1 24 | — | 0.62× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Academia Government Group | $312.3M | 51% |
| Re Occurring Revenues | $114.1M | 18% |
| Life Sciences And Healthcare Group | $98.3M | 16% |
| Transactional Revenues | $97.1M | 16% |
SPNT
暂无分部数据
